05-JUL-2022 6:10

MELAN ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1801-Melan, Adv, Adj vs Neoadj Pembrolizumab 1 N 1 Adjuvant Arm 342 173 49 21 8 0 0 02/15/2019 312 122
        2 Neoadjuvant Pembrolizumab   172 46 22 8 0 0      
            345 95 43 16 0 0      
 
    2 Y 3 Surgery   314 94 45 24 5 2 02/15/2019    
            314 94 45 24 5 2      
 
    3 Y 4 Post-Surgery Pembro   261 86 41 21 9 0 02/15/2019    
            261 86 41 21 9 0      
 
  S2000-MELAN, M1d/ BRAF, Enco+Bini+Nivo vs Ipil+Nivo 1 Y 1 Encorafenib/Binimetinib/Nivolu 112 5 3 0 0 0 0 01/06/2021 108 50
        2 Ipilimumab + Nivolumab   7 4 2 2 1 0      
            12 7 2 2 1 0      
 
Yes EA6141-Melan, Adv, Nivolumab+Ipi ± Sargmostim 1 E Total Registrations   46 7 4 3 0 0 03/25/2016 187 82
            46 7 4 3 0 0      
 
No EA6174-Merkel, Adjuvant Pembrolizumab vs Observation 1 E Total Registrations   42 16 6 2 0 0 05/01/2019 279 109
            42 16 6 2 0 0      
 
  EA6192-Melan, Adv, Erly Discont of Antibdy Thrpy 0 E Total Registrations   2 2 1 0 0 0 09/22/2021 136 45
            2 2 1 0 0 0      
 
    1 E Total Registrations   3 3 1 0 0 0 09/22/2021    
            3 3 1 0 0 0